ECCO 2026 at a Glance
Get ready for ECCO 2026. LucidQuest’s preview brings together the most relevant scientific and AI-driven advances in Crohn’s and Colitis research, helping you focus on high-impact sessions and plan a clear, insight-driven agenda.
📅 Build your schedule around the topics that matter most.
📥 Download the ECCO 2026_Preview_by_LucidQuest
Dive deeper
Key Topics from ECCO 2026 Scientific Presentations
Treatment Efficacy and Safety
Combination therapies and novel small molecules (obefazimod, risankizumab, picankibart) will lift UC and CD remission, supporting durable disease control.
Clinical and Post-Surgical Management
Dietary programs, biologics, and appendectomy or other post-surgical strategies will improve long-term remission and reduce escalation to advanced therapies.
Disease Monitoring and New Technologies:
Computer vision scoring, predictive models, and imaging will standardize assessments and boost trial recruitment, accelerating IBD therapeutic development.
Microbiome and Biomarkers
FMT, prevention diets, and proteomic risk scores will enable earlier Crohn’s detection and personalized intervention before overt disease.
Patient Quality of Life and Social Aspects
Obefazimod-linked fatigue improvements will translate into better IBDQ and EQ-5D-5L outcomes, supporting comprehensive symptom management.
Artificial Intelligence and Machine Learning at ECCO 2026
Raman Spectroscopy MAO Prediction
ML on plasma and tissue spectra will predict major adverse outcomes, enabling non-invasive risk monitoring in IBD.
Immune Signature Biomarkers
ML will surface circulating immune cell and repertoire signals to refine IBD diagnosis, stratification, and treatment selection.
Blood Transcriptome Severity
Models will predict UC endoscopic severity with AUC 0.81–0.87, supporting non-invasive disease activity tracking.
Personalized Drug Response:
Patient-level models will forecast drug response from transcriptomics and outcomes, improving trial enrichment and precision medicine.
Real-Time Endoscopy AI
Capsule endoscopy and colonoscopy tools will deliver real-time CD and UC assessments, improving diagnostic precision and decisions.
TACDPPM Progression Forecasting
Time-aware Crohn’s models will predict progression, surgery, and treatment outcomes, reaching AUROC 0.729–0.979.
📅 Build your schedule around the sessions that matter most.
📥 Download the ECCO 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.